US/UK/Canada

Share

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Pick a time period -
Tags ( Active)

Interim Report, January-June 2016

January-June 2016 ·  Net sales reached SEK 9,330 million (9,735), corresponding to a decrease of 4% and a flat organic sales development compared with the previous year. ·  EBITDA, excluding non-recurring items, was SEK 2,832 million (3,183), corresponding to a margin of 30.4% (32.7). ·  Non-recurring items related to the Mylan offer had a SEK 309 million negative impact on earnings before tax. ·  Profit after tax amounted to SEK 589 million (618). ·  Earnings per share reached SEK 1.61 (1.69). Excluding non-recurring items, earnings per share totaled SEK 1.65 (1.93). ·

Interim Report, January-March 2016

January-March 2016 · Net sales reached SEK 4,315 million (4,583), corresponding to a decrease of 6% and an organic sales development of -2%, compared with the previous year. · EBITDA, excluding non-recurring items, was SEK 1,256 million (1,403), corresponding to a margin of 29.1% (30.6). · Non-recurring items related to the Mylan offer had a SEK 121 million negative impact on earnings before tax. · Profit after tax amounted to SEK 291 million (226). · Earnings per share reached SEK 0.80 (0.62). Excluding non-recurring items, earnings per share totaled SEK 0.46 (0.59). ·

Year-end Report, January-December 2015

January-December 2015[1] · Net sales reached SEK 19,648 million (15,352), corresponding to an increase of 28%, 21% at constant exchange rates, compared with the previous year. · EBITDA, excluding non-recurring items, was SEK 6,482 million (4,700), corresponding to an increase of 38%, and a margin of 33.0% (30.6). · Non-recurring items had a SEK 698 million negative impact on earnings before tax. · Profit after tax amounted to SEK 1.192 million (402). · Earnings per share reached SEK 3.22 (1.23)[2]. Excluding non-recurring items, earnings per share totaled SEK 4.14 (3.64)[2].

Statement by the Board of Directors of Meda in relation to the public offer by Mylan

The Board of Directors of Meda unanimously recommends that the shareholders of Meda accept the offer made by MylanBackground This statement is made by the Board of Directors (the “Board”) of Meda AB (publ.) (“Meda” or the “Company”) pursuant to Section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). Mylan N.V., a leading global pharmaceutical company whose ordinary shares (“Mylan Shares”) are traded on the NASDAQ Global Select Market and the Tel Aviv Stock Exchange under the symbol “MYL”, has today announced a public offer to the shareholders of Meda to transfer all

Meda divests manufacturing unit Euromed in Spain

Meda has entered into a definitive agreement with The Riverside Company (“Riverside”) for the sale of Euromed S.A. (“Euromed”), a business-to-business manufacturer of herbal extracts and natural active substances located in Spain. The total consideration is EUR 82 million in upfront cash for the shares of Euromed. The unit generates sales of around EUR 40 million and an EBITDA margin of around 20% on an annual basis. Euromed is a legacy Rottapharm subsidiary, now part of Meda, and has historically been the supplier of the key Legalon API. Meda and Riverside have entered into a favorable

Interim Report, January-September 2015

January-September 2015[1] · Net sales reached SEK 14,629 million (10,198), corresponding to an increase of 43%, 34% at constant exchange rates compared to the previous year. · EBITDA, excluding non-recurring items, was SEK 4,856 million (2,946), corresponding to an increase of 65%, and a margin of 33.2% (28.9). · Non-recurring items had a SEK 677 million negative impact on earnings before tax. · Profit after tax amounted to SEK 781 million (677). · Earnings per share reached SEK 2.14 (2.15)[2]. Excluding non-recurring items, earnings per share totaled SEK 3.03 (2.17). ·

Interim Report, January-June 2015

January-June 2015[1] · Net sales reached SEK 9,735 million (6,842), corresponding to an increase of 42%, 31% at constant exchange rates compared to the previous year. · EBITDA, excluding non-recurring items, was SEK 3,183 million (1,961), corresponding to an increase of 62%, and a margin of 32.7% (28.7). · Non-recurring effects had a SEK 308 million negative impact on earnings before tax. · Profit after tax amounted to SEK 618 million (503). · Earnings per share reached SEK 1.69 (1.60)[2]. Excluding non-recurring effects, earnings per share totaled SEK 1.93 (1.47). ·

The terms regarding the rights issue in Meda are set

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan, Hong Kong, New Zealand, South Africa or any other jurisdiction where such distribution of this press release would be subject to legal restrictions On 10 October 2014, Meda AB announced a rights issue of approximately SEK 2 billion, in order to finance part of the acquisition of the Italian specialty pharma company Rottapharm S.p.A. Today, the Board of Directors of Meda announces the final terms for the rights issue. Summary · Shareholders in Meda has

Interim Report, January-September 2014

January-September 2014 · Net sales reached SEK 10,198 million (9,664), corresponding to an increase of 6% and an organic growth[1] of 3% compared to previous year. · EBITDA amounted to SEK 2,978 million (2,719), corresponding to a 29.2% margin (28.1). · Operating profit amounted to SEK 1,283 million (1,087). · Profit after tax amounted to SEK 677 million (547). · Earnings per share reached SEK 2.24 (1.82). · Cash earnings per share amounted to SEK 6.34 (6.48). · Forecast for full-year 2014 “Meda expect sales for full-year 2014 to reach SEK 15 billion and that the

Meda to acquire Rottapharm, creating a European specialty pharma leader

·The combined entity will have enhanced scale, reach and profitability with 2013 pro-forma revenue and EBITDA of SEK 18 billion (€1.9 billion)[1]  and SEK 5 billion (€0.5 billion) respectively ·Acquisition for SEK 21.2 billion (€2.275 billion) including net debt of SEK 2.8 billion (approx. €300 million) implying an equity value of SEK 18.4 billion (€1.975 billion) ·Increases revenue

Year-end report January–December 2013

January-December 2013 · Group net sales reached SEK 13,114 million (12,991), corresponding to organic growth[1] of 4% compared to last year. · EBITDA amounted to SEK 3,734 million (3,945), corresponding to a 28.5% margin (30.4). · Operating profit totaled SEK 1,548 million (1,801). · Profit after tax amounted to SEK 805 million (1,175[2]). · Earnings per share reached SEK 2.67 (3.98[2]). · Cash earnings per share reached SEK 8.89 (8.84). · Proposed dividend per share: SEK 2.50 (2.25). Fourth quarter 2013 · Group net sales reached SEK 3,450 million (3,195).

Meda acquires a new OTC product line in dental health

Meda has signed an agreement to acquire ZpearPoint AS, including global rights to its main product, EB24, an OTC line for treating dental erosion. Dental erosion is a common, growing condition that impacts all ages and for which there is currently no effective treatment. The condition is estimated to affect 15-50% of the population and it is sometimes referred to as the “new caries”. The EB24 product is based on hydrogen fluoride highly diluted in water. In studies, the product has shown that it is able to penetrate enamel surfaces and form calcium fluoride resulting in an anti-erosive

Interim report, January-September 2013

January-September 2013 · Group net sales reached SEK 9,664 million (9,796), corresponding to organic growth[1] of 2% compared to last year. · EBITDA amounted to SEK 2,719 million (3,050), corresponding to a 28.1% margin (31.1). · Operating profit totaled SEK 1,087 million (1,449). · Profit after tax amounted to SEK 547 million (818). · Earnings per share reached SEK 1.82 (2.77). · Cash earnings per share amounted to SEK 6.48 (6.18). · Forecast for full-year 2013 “The Meda Group expects to achieve sales of around SEK 13 billion and an EBITDA margin of around 28

Acquisition of Acton Pharmaceuticals completed

On August 30th, 2013, Meda announced the acquisition of Acton Pharmaceuticals, Inc. and its proprietary product Aerospan. The acquisition has now been completed. The purchase price for Acton amounted to 135 MUSD, on a cash and debt free basis. In addition, there is a milestone payment of 10 million USD and royalty based milestones. About Aerospan Aerospan (flunisolide HFA, 80 mcg) is approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of asthma in adult and pediatric patients 6 years of age and older. Aerospan is the first and only product registered in the US

CEO change for Meda AB

After 14 years as CEO at Meda, Anders Lönner has decided to step down from the position. The Board of Directors has named Dr. Jörg-Thomas Dierks as the new CEO. Dierks has been the Chief Operating Officer at Meda since 2005. Dierks is 53 years old and has an education as a medical doctor. He has long experience in the pharmaceutical industry at NovoNordisk and Viatris before coming to Meda. ”Every journey has to end. I’m very glad to be placing the organization in the hands of Jörg-Thomas, who is highly competent, experienced, and has strong organizational support,” says Anders Lönner. “

There are no items matching the current filter
There are no more items matching the current filter
Back to top